This clinical trial is focused on patients who have received a kidney transplant and are considered to have a low risk of immune system complications. The study is investigating the use of a medication called rabbit anti-human T-lymphocyte immunoglobulin, also known as Grafalon®. This medication is given through an intravenous infusion, which means it is administered directly into a vein. The main goal of the study is to determine the best dose of Grafalon® that can help prevent complications related to a condition called CD4 T cell lymphopenia, which is a decrease in a specific type of white blood cell that is important for the immune system.
Participants in the study will receive Grafalon® for a short period, and the effects will be monitored over time. The study will look at how the medication affects the immune system, particularly the levels of different types of blood cells, and will also track any side effects or adverse events that may occur. The study aims to find a dose that is effective in preventing complications without causing significant side effects.
Throughout the study, researchers will also observe the overall health of the participants, including their kidney function and any potential infections or other health issues that may arise after the transplant. The study will help to improve understanding of how to best use Grafalon® in kidney transplant patients to support their recovery and long-term health.
France 
